Clinical Observation Of The Treatment Of Fuhe Beihua Formula Joint Catgut Embedding Therapy Of The Liver Fibrosis Of Primary Hepatocellular Carcinoma After Interventional Therapy

Objective: To observe the clinical effect of the treatment of Fuhe Beihua Formula joint catgut embedding therapy of the liver fibrosis of primary hepatocellular carcinoma after interventional therapy.Preliminary evaluate the value of the treatment of Fuhe Beihua Formula joint catgut embedding therapy of the liver fibrosis of primary hepatocellular carcinoma after interventional therapy.Provide theoretical and practical basis for traditional Chinese medicine to inhibit or reverse TACE postoperative hepatic fibrosis and reduce the damage of liver function,so as to improve the antitumor effect.Methods: 72 patients met the inclusion criteria of patients with primary hepatocellular carcinoma by 1: 1 ratio were divided into treatment group(Fuhe Beihua Formula joint catgut embedding therapy group)and control group(conventional treatment group)with 36 cases in each group.The two group were treated with TACE operation.The experimental group also take the treatment of Fuhe Beihua Formula joint catgut embedding therapy.All patients treated with TACE detect the following indicators 24 h before and after 4 weeks:(1)liver function: ALT、AST、TBIL、ALP、GGT;(2)Four items of liver fibrosis: HA、LN、PⅢNP、C-Ⅳ;(3)APRI score;(4)FIB-4;(5)LSM;(6)Clinical symptoms.Records of all experimental data and variation for statistical analysis and data analysis.In order to preliminary evaluation the treatment effect of Fuhe Beihua Formula joint catgut embedding therapy of the liver fibrosis of primary hepatocellular carcinoma after interventional therapy.Results:(1)The treatment group and the control group is in a balance and no significant difference in gender,age,the grade of Child-Pugh(P>0.05),they were comparable between the two groups.(2)There are no significant differences in TBIL,ALP,GGT between the two groups before and after treatment(P>0.05).After treatment,there is a significant differences in ALT and AST of treatment group when compared with before(P<0.05).There are no statistically significant differences between the two groups after treatment in the index of TBIL,ALP and GGT(P>0.0 5).There are a statistically significant differences between the two groups after treatment in the index of ALT and AST(P<0.05).(3)Two groups of patients of liver fibrosis indexes of HA,LN,PIIINP and C-IV showed no statistical significance before treatment(P>0.05),the index of liver fibrosis also increased to different extent after treatment;the control group of four indexes of liver fibrosis were significantly higher after treatment(P<0.01).(4)The APRI score of treatment group decreased after treatment(P<0.05),while the control group increased(P<0.05).The APRI scores of the two groups are significantly different after treatment(P<0.05).(5)The FIB-4 of treatment group decreased after treatment(P<0.05),while the control group increased(P<0.05).The FIB-4 of the two groups are significantly different after treatment(P<0.05).(6)The two groups has significant differences in LSM when compared with before respectively.The observation group has a significant difference in LSM when compared with the control group after treatment(P<0.01).(7)There are no statistically significant differences between the two groups in clinical symptoms before the treatment(P>0.05).After the treatment,there is a statistically significant differences between the two groups in clinical symptoms(P<0.01).There is a significant difference between the two groups in total effective integration(P<0.05).Conclusion: Fuhe Beihua Formula joint catgut embedding therapy can improve the index of ALT、AST.It means Fuhe Beihua Formula can protect the liver cells in a certain extent.Fuhe Beihua Formula joint catgut embedding therapy can improve the four indexes of liver fibrosis,APRI scores,FIB-4,LSM.It means Fuhe Beihua Formula can reduce the synthesize of collagen and improve the progress of liver fibrosis.Fuhe Beihua Formula joint catgut embedding therapy can significantly reduce the symptom scores of the treatment group.It suggesting that Fuhe Beihua Formula joint catgut embedding therapy can significantly improve clinical symptoms of patients with primary hepatocellular carcinoma after TACE,and improve the quality of life.